Kepler Capital Remains a Hold on AstraZeneca (AZN)
Needham Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Biogen Analyst Ratings
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $282
RBC Capital Adjusts Price Target on Biogen to $282 From $303
AstraZeneca (AZN) Receives a Hold From DZ BANK AG
Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294
Buy Rating on Biogen: Anticipating Positive Reversal and Global Market Strength for Lecanemab
BMO Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Raises Target Price to $89
Vertex Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,125
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Analysts' Opinions Are Mixed on These Healthcare Stocks: Align Tech (ALGN) and Gilead Sciences (GILD)
Hold Rating on Gilead Sciences Amidst Q2 Revenue Shortfall and Competitive Pressures
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $136
AstraZeneca's Strong Q2 Performance and Positive Outlook Justify Buy Rating
Jefferies Remains a Hold on AstraZeneca (AZN)
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), AstraZeneca (AZN) and Icon (ICLR)